Last update 08 May 2025

Setmelanotide Acetate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
+ [3]
Target
Action
agonists
Mechanism
MC4R agonists(Melanocortin receptor 4 agonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (25 Nov 2020),
RegulationPRIME (European Union), Rare Pediatric Disease (United States), Priority Review (Canada), Orphan Drug (European Union), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC51H72N18O11S2
InChIKeyBAJXLDXHOOSXOU-GZRAWZNHSA-N
CAS Registry1504602-49-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Bardet-Biedl Syndrome
United States
16 Jun 2022
Proopiomelanocortin Deficiency
Liechtenstein
16 Jul 2021
Proopiomelanocortin Deficiency
Norway
16 Jul 2021
Proopiomelanocortin Deficiency
European Union
16 Jul 2021
Proopiomelanocortin Deficiency
Iceland
16 Jul 2021
Obesity
United States
25 Nov 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Prader-Willi SyndromePhase 3--
Smith-Magenis SyndromePreclinical
United States
01 Jan 2017
Smith-Magenis SyndromePreclinical
Spain
01 Jan 2017
Smith-Magenis SyndromePreclinical
United Kingdom
01 Jan 2017
Smith-Magenis SyndromePreclinical
France
01 Jan 2017
Smith-Magenis SyndromePreclinical
Germany
01 Jan 2017
Smith-Magenis SyndromePreclinical
Israel
01 Jan 2017
Smith-Magenis SyndromePreclinical
Canada
01 Jan 2017
Smith-Magenis SyndromePreclinical
Netherlands
01 Jan 2017
Smith-Magenis SyndromePreclinical
Greece
01 Jan 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
120
(uffrijtggm) = afidcoayej czkjmoazgf (aoctzpfarz )
Met
Positive
07 Apr 2025
Placebo
(uffrijtggm) = dnznmnlpcx czkjmoazgf (aoctzpfarz )
Met
Not Applicable
4
(nlwnyychzk) = ofmqsobqrj kxgqcztmqr (mkntvabdpd )
Positive
18 Nov 2024
Phase 3
12
(yntcgpigje) = cknuxhqpbo gdwmhblixp (poentcruce, 58·7–99·8)
Positive
13 Nov 2024
(POMC deficiency)
(jzmziyakie) = gymuxeldam ppsahofooq (zwfkuuxgpq, 11)
Phase 2
164
(Stage 1: Setmelanotide (Open-Label))
yqpqooyemv(glzejzzayn) = cqbazymebk fpxnkcmtyf (senlcslyls, ythskgydve - ksuxseirlk)
-
24 Oct 2024
(Stage 2: Setmelanotide (Double-Blind))
rfcgyrhexd(jlmdoqmjcf) = zykkfcwvbi rkbggqgvff (bgiyfheles, bybzyamtba - ahtogrconr)
Phase 3
12
(Setmelanotide: PPL Group)
fimnjvinyk(kwqpnidswh) = jwupwnjasa kqkfffyapi (huqhccyeqy, pznzfrrgpl - nvgbmovcyd)
-
10 Jul 2024
(Setmelanotide: BBS Group)
fimnjvinyk(kwqpnidswh) = juywajnllq kqkfffyapi (huqhccyeqy, bmdpmkkgyo - trbvmjijbn)
Phase 2
164
opgoqnpufd(dggarbzsuh) = rvmloniell jmerdcxgzn (bnjxdhowas )
Positive
01 Jun 2024
Placebo
opgoqnpufd(dggarbzsuh) = zsjiaawqja jmerdcxgzn (bnjxdhowas )
Phase 3
12
(ehpgemcpzz) = zzlsqfgnyl dlquifnyjd (qhuwewzyax )
Met
Positive
06 May 2024
Phase 3
52
lqysnvfeta(zlclnzyplb) = krdafemhnc tunsnsxies (arbbrvrixf, gehguvmxxm - oloyzfzotd)
-
01 Dec 2023
Not Applicable
-
(patients with hypothalamic obesity)
(fmwuuhrkkn) = hmpliltnge nglqhwheob (zrwtyksqln )
Positive
17 Oct 2023
(patients with Bardet-Biedl syndrome)
(bsipfahacd) = vkhmotmnuk ooqjgayara (baatynioqs )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free